{
  "id": "63ac0dba0e0e9f59",
  "title": "Opna Bio OPN - 2853 secures FDA orphan drug status for myelofibrosis",
  "description": "20260122T133000Z",
  "content": "",
  "source": "pharmaceutical-business-review.com",
  "source_url": "https://www.pharmaceutical-business-review.com/news/opna-bios-opn2853-fdas-status/",
  "published_at": "20260122T133000Z",
  "fetched_at": "2026-01-23T00:24:24.269073+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "drug",
    "fda"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.pharmaceutical-business-review.com/news/opna-bios-opn2853-fdas-status/",
    "url_mobile": "https://www.pharmaceutical-business-review.com/news/opna-bios-opn2853-fdas-status/amp/",
    "title": "Opna Bio OPN - 2853 secures FDA orphan drug status for myelofibrosis",
    "seendate": "20260122T133000Z",
    "socialimage": "https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/01/PT-22-01-2026-shutterstock_2314970855.jpg",
    "domain": "pharmaceutical-business-review.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}